OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet HIV is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Argentina updates HIV laws	276
Evidence supports use of on-demand PrEP for HIV prevention	145
Transplant donation without discrimination	137
How do we prevent anal cancer in people living with HIV?	135
Lenacapavir: an attractive option, but proceed with caution	111
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	107
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	106
Correction to Lancet HIV 2022; 9: e791–800	103
How much could long-acting PrEP cost in South Africa?	99
The Australian AIDS crisis through the eyes of volunteers	94
HIV and COVID-19: juxtaposition of two pandemics	87
Optimising anal cancer screening through risk stratification	86
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	84
Are we ready for long-acting HIV treatment for adolescents?	79
Lung cancer in people living with HIV	77
A moment of reckoning	77
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	77
Steps toward quick and equitable roll-out of lenacapavir	70
Risk estimation in HIV reveals our usual blind spots	69
Controversial chronicler of LGBTQ rights	62
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	58
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	57
Unheard testimony	56
Game-changing study of second-line HIV treatment	55
Stigma reduction is key to improving the HIV care continuum	54

Gains and gaps: addressing HIV in diverse sex worker groups	52
All roads lead to Westminster: the infected blood scandal	49
Redefining care: injectable HIV treatment for adolescents	48
Fate of people with HIV in jeopardy in Ukraine	48
Making America unhealthy again	48
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	47
Suicide prevention research is crucial to achieving health equity for people with HIV	46
Equitable access to long-acting PrEP on the way?	46
Reducing HIV transmission in British Columbia, Canada	45
Recent gay Black history in the UK	45
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	44
WHO recommends lenacapavir for HIV prevention	43
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial	42
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi	42
Sex as a biological variable in HIV-1 and schistosome co-infection	42
Integration of sexual health and HIV services	41